(MENAFN- PR Newswire) DUBLIN, March 12, 2024 /PRNewswire/ --
The "Global IgG Mediated Autoimmune Diseases Biologic Drugs market (2024 Edition): Analysis By Antibody Source (Humanized, Fully Human, Chimeric, Other Sources), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to
ResearchAndMarkets's offering.
The Global
IgG Mediated Autoimmune Diseases Biologic Drugs market showcased growth at a CAGR of 7.25% during 2019-2022. The market was valued at USD 123.99 Billion in 2022 which is expected to reach USD 197.78 Billion in 2029.
The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, South India).
The increasing incidence and prevalence of IgG mediated autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis are major drivers for the growth of biologic drugs. Factors such as genetic predisposition, environmental triggers, and lifestyle changes contribute to the rising burden of autoimmune diseases globally. Additionally, The aging population worldwide is more susceptible to autoimmune diseases, driving the demand for biologic drugs. Elderly individuals often experience multiple comorbidities and may require more targeted and effective treatments, contributing to the expansion of the biologic drugs market.
Biologic drugs for IgG mediated autoimmune diseases represent a significant advancement in medical treatment, as they are meticulously engineered to selectively target key components of the immune system implicated in the pathogenesis of these diseases. This precision targeting distinguishes them from conventional treatments, which often have broader mechanisms of action and can lead to more generalized effects.
For instance, these biologic drugs may directly inhibit certain pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-?) or interleukins (ILs), which play crucial roles in promoting inflammation and tissue damage in autoimmune conditions like rheumatoid arthritis or inflammatory bowel disease. By specifically targeting these cytokines, biologic therapies can disrupt the inflammatory cascade at its source, thereby alleviating symptoms and preventing disease progression more effectively than traditional therapies.
The global market for IgG mediated autoimmune diseases biologic drugs is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.
Scope of the Report
The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market by Value (USD Billion). The report presents the analysis of IgG Mediated Autoimmune Diseases Biologic Drugs Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029. The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Antibody Source (Humanized, Fully Human, Chimeric, Other Antibody Sources) The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Indication (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Other Indications). The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Antibody Sources, by mode of operation & by end users. Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report. The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
Analyst Recommendations
Shift towards targeted therapies and personalized medicine Adoption of biosimilars and biobetters
Competitive Positioning
Companies' Product Positioning Market Position Matrix Market Share Analysis of IgG-mediated Autoimmune Disease Biologic Drugs Market
Company Profiles
Johnson & Johnson Pfizer Novartis AG Roche Holding AG Eli Lilly and Company Abbvie Inc. Sanofi GSK plc. UCB S.A
For more information about this report visit
About ResearchAndMarkets
ResearchAndMarkets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
MENAFN12032024003732001241ID1107969402
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.